CMS Urged To Cover Beta Amyloid PET Scans For Alzheimer's, But Cautiously
This article was originally published in The Gray Sheet
Executive Summary
Imaging stakeholders call for Medicare coverage of beta amyloid positron emission tomography scans to help diagnose and manage dementia patients, but clinical societies warn against using the technology as a screening tool for Alzheimer’s disease. CMS took comments through Nov. 8 on its ongoing national coverage analysis.
You may also be interested in...
Imaging Groups Oppose CMS Coverage Proposal For Beta-Amyloid PET
Medical imaging manufacturers and professional societies echoed Eli Lilly’s criticism of the CMS proposal to cover beta-amyloid PET for use in patients suffering from dementia and neurodegenerative disease.
Trial-Only Medicare Coverage Proposed For PET Alzheimer’s Scans
Beta amyloid positron emission tomography scans to help diagnose dementia would only be covered by Medicare as part of a clinical trial under a proposed national coverage decision. Eli Lilly requested broader coverage for its Amyvid PET imaging agent.
Medicare Panel Finds Little Support For Amyloid PET Imaging Changes
MedCAC panel has limited confidence that there is enough evidence to show beta amyloid positron emission tomography imaging of the brain changes health outcomes. The vote does not bode well for the technology’s coverage proposal due in July.